Targeting DNA-repair systems brings hopes to cancer patients

CAS researchers have recently raised a hypothesis to circumvent tumor resistance to radio-and

Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention results from a propensity score-matched analysis of the evaluation of drug-eluting stents and ischemic events (EVENT) registry

Background Prior randomized trials have shown reduced bleeding with bivalirudin compared with unfractionated heparin （UFH） in patients undergoing percutaneous coronary intervention （PCI）. However, it is not known if this benefit is also present when UFH doses are more tightly controlled （as measured by activated clotting time, ACT）.